December 15, 2022
Personalizing Breast Cancer Care: The Impact of Two Clinical Studies
At this year’s San Antonio Breast Cancer Symposium (SABCS), new data was presented from two long-term clinical studies: TAILORx and RxPONDER. Launched over a decade ago, both studies used the Oncotype DX Breast Recurrence Score® test to identify more precisely which breast cancer patients will truly benefit from chemotherapy.
These studies continue to be essential in providing patients and providers with the confidence to help make informed treatment decisions. To better understand how this data impacts breast cancer care, hear from Dr. Jennifer Racz, Director of U.S. Medical Affairs, Oncology at Exact Sciences as she elaborates on the latest findings.
